You are here

Discovery of inhibitors of the metabolic oncogene 3-phosphoglycerate dehydrogenas

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA176897-01A1
Agency Tracking Number: R43CA176897
Amount: $172,052.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
450 E 29TH ST
NEW YORK, NY 10016-8367
United States
DUNS: 962923947
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 KELLEN OLSZEWSKI
 (212) 308-6000
 kellen@kadmon.com
Business Contact
 PETER MILLS
Phone: (212) 308-6000
Email: peter@kadmon.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Many profound metabolic alterations have been described in solid tumors which present attractive therapeutic targets. One recently described metabolic oncogene is 3- phosphoglycerate dehydrogenase (PHGDH), the rate-limiting step in the pathway synthesizing serine and glycine for proteins, lipids, folate and nucleotide metabolism. The PHGDH gene is amplified at the genomic level across a wide spectrum of human cancers, and is particularly associated with certain treatment-resistant subtypes, such as triple-negative breast cancers, that present a major unmet clinical need for novel, safe and effective therapeutics. PHGDH knockdown has been demonstrated to be specifically toxic to PHGDH-amplified cell lines both in culture and in xenograft models. However, to date no specific inhibitors of mammalian PHGDH have yet been described, severely limiting investigation into this exciting new cancer target. To address this need Kadmon Corporation has initiated a project towar

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government